HRP20191683T1 - Liofilizirani liposomi - Google Patents
Liofilizirani liposomi Download PDFInfo
- Publication number
- HRP20191683T1 HRP20191683T1 HRP20191683T HRP20191683T1 HR P20191683 T1 HRP20191683 T1 HR P20191683T1 HR P20191683 T HRP20191683 T HR P20191683T HR P20191683 T1 HRP20191683 T1 HR P20191683T1
- Authority
- HR
- Croatia
- Prior art keywords
- liposomes
- composition according
- composition
- agents
- mol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161550047P | 2011-10-21 | 2011-10-21 | |
| PCT/US2012/060293 WO2013059133A1 (en) | 2011-10-21 | 2012-10-15 | Lyophilized liposomes |
| EP12841616.1A EP2768484B1 (en) | 2011-10-21 | 2012-10-15 | Lyophilized liposomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191683T1 true HRP20191683T1 (hr) | 2019-12-13 |
Family
ID=48141268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191683 HRP20191683T1 (hr) | 2011-10-21 | 2012-10-15 | Liofilizirani liposomi |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10028912B2 (enExample) |
| EP (2) | EP2768484B1 (enExample) |
| JP (6) | JP6133308B2 (enExample) |
| KR (5) | KR102024836B1 (enExample) |
| CN (2) | CN104114156A (enExample) |
| AU (1) | AU2012326370C9 (enExample) |
| BR (1) | BR112014009305B1 (enExample) |
| CA (1) | CA2852777C (enExample) |
| DK (1) | DK2768484T3 (enExample) |
| ES (1) | ES2750368T3 (enExample) |
| FR (1) | FR19C1063I2 (enExample) |
| HR (1) | HRP20191683T1 (enExample) |
| HU (2) | HUE045978T2 (enExample) |
| IL (1) | IL232161B (enExample) |
| LU (1) | LUC00135I2 (enExample) |
| NL (1) | NL301016I2 (enExample) |
| NO (1) | NO2019041I1 (enExample) |
| PL (1) | PL2768484T3 (enExample) |
| PT (1) | PT2768484T (enExample) |
| RU (1) | RU2648753C2 (enExample) |
| SI (1) | SI2768484T1 (enExample) |
| WO (1) | WO2013059133A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20191683T1 (hr) * | 2011-10-21 | 2019-12-13 | Jazz Pharmaceuticals Res Llc | Liofilizirani liposomi |
| US11504322B2 (en) | 2014-08-28 | 2022-11-22 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
| US11471401B2 (en) | 2014-08-28 | 2022-10-18 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
| CA2958769A1 (en) | 2014-08-28 | 2016-03-03 | The General Hospital Corporation | Compositions and methods for treatment of neurological disorders |
| US11298318B2 (en) * | 2015-04-13 | 2022-04-12 | Fountain Technologies International, Llc | One-step method for production of ultra-small lipid structures |
| CN113679689B (zh) | 2015-07-22 | 2023-09-01 | 日东电工株式会社 | 用于纳米粒冷冻干燥物形式的组合物及方法 |
| IL292080B2 (en) | 2015-11-11 | 2024-09-01 | Celator Pharmaceuticals Inc | Treatment regimens for hematologic cancers and methods of use thereof |
| SG10201913504XA (en) | 2016-02-26 | 2020-03-30 | Massachusetts Gen Hospital | Medical ice slurry production and delivery systems and methods |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CA3069019A1 (en) * | 2017-07-10 | 2019-01-17 | Immunovaccine Technologies Inc. | Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof |
| WO2020068979A1 (en) | 2018-09-25 | 2020-04-02 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
| AU2020231916B2 (en) | 2019-03-01 | 2025-08-28 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| EP3990041B1 (en) * | 2019-06-28 | 2025-08-06 | Board of Regents, The University of Texas System | Method of reconstituting liposomal annamycin |
| EP4003295A1 (en) * | 2019-07-24 | 2022-06-01 | The General Hospital Corporation | Methods of creating a substance with different freezing points by encapsulation |
| US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| CN115252563B (zh) * | 2022-06-24 | 2024-07-12 | 石药集团中奇制药技术（石家庄）有限公司 | 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法 |
| CN116003493B (zh) * | 2022-12-16 | 2025-02-28 | 常州金远药业制造有限公司 | 一种二价铜离子及阿糖胞苷的回收方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| JPS62501631A (ja) * | 1985-01-11 | 1987-07-02 | ザ・リ−ジェンツ・オブ・ジ・ユニバ−シィティ・オブ・カリフォルニア | リポソ−ムの保持法 |
| CA1256372A (en) | 1985-04-11 | 1989-06-27 | Koichiro Miyazima | Process for producing liposome composition |
| US4927571A (en) | 1987-05-18 | 1990-05-22 | Liposome Technology, Inc. | Preparation of injectable doxorubicin/liposome suspension |
| US4915951A (en) | 1987-12-03 | 1990-04-10 | California Institute Of Technology | Cryoprotective reagent |
| DE68916439T2 (de) * | 1988-10-05 | 1994-10-20 | Vestar Inc | Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens. |
| US5049392A (en) * | 1989-01-18 | 1991-09-17 | The Liposome Company, Inc. | Osmotically dependent vesicles |
| IL125800A0 (en) * | 1996-02-19 | 1999-04-11 | Nycomed Imaging As | Thermally stabilized contrast agent |
| IT1289938B1 (it) * | 1997-02-20 | 1998-10-19 | Angelini Ricerche Spa | Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e |
| GB9813100D0 (en) | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
| NZ516648A (en) | 1999-07-16 | 2004-01-30 | Alza Corp | A liposome composition having resistance to freeze/thaw damage |
| US6984395B2 (en) * | 2001-04-11 | 2006-01-10 | Qlt, Inc. | Drug delivery system for hydrophobic drugs |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| AU2002331481B2 (en) | 2001-10-03 | 2008-04-24 | Celator Pharmaceuticals, Inc. | Liposome loading with metal ions |
| EP1443900B1 (en) * | 2001-11-13 | 2012-05-23 | Celator Pharmaceuticals, Inc. | Lipid carrier compositions with enhanced blood stability |
| EP1448165B1 (en) | 2001-11-13 | 2007-09-19 | Celator Pharmaceuticals, Inc. | Lipid carrier compositions and methods for improved drug retention |
| AU2003287526A1 (en) | 2002-11-06 | 2004-06-03 | Protein-stabilized liposomal formulations of pharmaceutical agents | |
| US20060240090A1 (en) * | 2003-04-02 | 2006-10-26 | Lawrence Mayer | Combination compositions of camptothecins and fluoropyrimidines |
| AU2005235455B2 (en) * | 2004-04-22 | 2011-01-20 | Jazz Pharmaceuticals Therapeutics, Inc. | Liposomal formulations of anthracycline agents and cytidine analogs |
| US7893338B2 (en) | 2004-07-15 | 2011-02-22 | Creative Technology Ltd | Method of composing music on a handheld device |
| US20060110441A1 (en) * | 2004-10-28 | 2006-05-25 | Harry Wong | Lyophilized liposome formulations and method |
| AU2005304914B2 (en) * | 2004-11-05 | 2012-02-16 | Tekmira Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal camptothecin formulations |
| US20080107722A1 (en) | 2004-11-18 | 2008-05-08 | Paul Tardi | Method For Loading Multiple Agents Into Delivery Vehicles |
| EP1951239A2 (en) | 2005-10-25 | 2008-08-06 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
| WO2007076117A2 (en) | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
| ES2909903T3 (es) | 2007-02-16 | 2022-05-10 | Rotalec Ip Holdings Llc | Proporciones fijas de medicamentos para el tratamiento de cáncer hematopoyético y trastornos proliferativos |
| ES2550759T3 (es) | 2007-08-17 | 2015-11-12 | Celator Pharmaceuticals, Inc. | Formulaciones farmacológicas de platino mejoradas |
| KR101563658B1 (ko) | 2007-11-28 | 2015-10-27 | 셀라토 파마슈티칼즈, 인코포레이티드 | 개선된 탁산 전달 시스템 |
| EP2344161B1 (en) | 2008-10-16 | 2018-12-19 | Celator Pharmaceuticals, Inc. | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
| ES2547698T3 (es) | 2009-12-03 | 2015-10-08 | Jiangsu Hengrui Medicine Co., Ltd. | Liposoma de irinotecán o su clorhidrato y método de preparación del mismo |
| EP2531175A2 (en) | 2010-02-01 | 2012-12-12 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Liposomes comprising amphipathic drugs and method for their preparation |
| HRP20191683T1 (hr) * | 2011-10-21 | 2019-12-13 | Jazz Pharmaceuticals Res Llc | Liofilizirani liposomi |
-
2012
- 2012-10-15 HR HRP20191683 patent/HRP20191683T1/hr unknown
- 2012-10-15 JP JP2014537142A patent/JP6133308B2/ja active Active
- 2012-10-15 HU HUE12841616A patent/HUE045978T2/hu unknown
- 2012-10-15 KR KR1020147012039A patent/KR102024836B1/ko active Active
- 2012-10-15 PL PL12841616T patent/PL2768484T3/pl unknown
- 2012-10-15 EP EP12841616.1A patent/EP2768484B1/en not_active Revoked
- 2012-10-15 RU RU2014120475A patent/RU2648753C2/ru active
- 2012-10-15 CN CN201280059606.1A patent/CN104114156A/zh active Pending
- 2012-10-15 KR KR1020197027220A patent/KR102113753B1/ko active Active
- 2012-10-15 KR KR1020227034406A patent/KR20220141906A/ko not_active Ceased
- 2012-10-15 CN CN201810733439.3A patent/CN108853031A/zh active Pending
- 2012-10-15 CA CA2852777A patent/CA2852777C/en active Active
- 2012-10-15 BR BR112014009305-9A patent/BR112014009305B1/pt active IP Right Grant
- 2012-10-15 ES ES12841616T patent/ES2750368T3/es active Active
- 2012-10-15 PT PT128416161T patent/PT2768484T/pt unknown
- 2012-10-15 KR KR1020217023773A patent/KR102452305B1/ko active Active
- 2012-10-15 US US14/352,662 patent/US10028912B2/en active Active
- 2012-10-15 AU AU2012326370A patent/AU2012326370C9/en active Active
- 2012-10-15 KR KR1020207013990A patent/KR102284689B1/ko active Active
- 2012-10-15 WO PCT/US2012/060293 patent/WO2013059133A1/en not_active Ceased
- 2012-10-15 EP EP19183846.5A patent/EP3572071A1/en active Pending
- 2012-10-15 DK DK12841616.1T patent/DK2768484T3/da active
- 2012-10-15 SI SI201231668T patent/SI2768484T1/sl unknown
-
2014
- 2014-04-22 IL IL232161A patent/IL232161B/en active IP Right Grant
-
2017
- 2017-04-04 JP JP2017074348A patent/JP6359717B2/ja active Active
-
2018
- 2018-02-07 US US15/891,170 patent/US10166184B2/en active Active
- 2018-05-17 JP JP2018095127A patent/JP6592556B2/ja active Active
- 2018-11-05 US US16/181,203 patent/US10835492B2/en active Active
-
2019
- 2019-09-20 JP JP2019172314A patent/JP2020007367A/ja active Pending
- 2019-10-10 HU HUS1900047 patent/HUS1900047I1/hu unknown
- 2019-10-23 FR FR19C1063C patent/FR19C1063I2/fr active Active
- 2019-10-24 LU LU00135C patent/LUC00135I2/fr unknown
- 2019-10-25 NL NL301016C patent/NL301016I2/nl unknown
- 2019-11-25 NO NO2019041C patent/NO2019041I1/no unknown
-
2020
- 2020-11-13 US US17/097,530 patent/US20210169803A1/en not_active Abandoned
-
2021
- 2021-12-03 JP JP2021196626A patent/JP7476161B2/ja active Active
-
2022
- 2022-07-13 US US17/812,414 patent/US20230172855A1/en active Pending
-
2024
- 2024-01-05 JP JP2024000732A patent/JP2024045183A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191683T1 (hr) | Liofilizirani liposomi | |
| JP2014532623A5 (enExample) | ||
| JP2024045183A5 (enExample) | ||
| JP2020007367A5 (enExample) | ||
| Chen et al. | An overview of liposome lyophilization and its future potential | |
| CU20090114A7 (es) | Formulación liposomal y proceso para la preparación del mismo | |
| JP2010519224A5 (enExample) | ||
| CA2906149C (en) | Controlled drug release liposome composition | |
| AR021074A1 (es) | COMPOSICIoN FARMACÉUTICA DE MOXIFLOXACINA, PROCEDIMIENTO PARA SU PRODUCCIoN, Y USO DE DICHA COMPOSICIoN PARA PREPARAR UN MEDICAMENTO ANTIBACTERIANO. | |
| Alinaghi et al. | Hydrogel-embeded vesicles, as a novel approach for prolonged release and delivery of liposome, in vitro and in vivo | |
| BR112012003283A8 (pt) | sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente. | |
| CL2011003046A1 (es) | Composicion farmaceutica que comprende 7-(2,5-dihidro-4-imidazo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk] [1,4]benzodiazepina, una sal o solvato, sbe7-b-cd y opcionalmente un tampon; proceso de preparacion; util para tratar cancer (div. sol. 1848-08). | |
| JP2019500318A (ja) | 細菌感染症を治療するための組成物及び方法 | |
| JP2010518086A5 (enExample) | ||
| WO2014003183A1 (ja) | パック基材、パック化粧料ならびにパック化粧料キット | |
| PT1220670E (pt) | Utilizacao de l-carnitina e seus derivados alcanoilos como agentes osmoticos em solucoes para utilizacao medica. | |
| WO2021161256A1 (en) | Patch product based on natural polymers | |
| JP2013518051A5 (enExample) | ||
| CN102940616A (zh) | 一种盐酸氨溴索口腔分散膜剂 | |
| CN102935078A (zh) | 一种布洛芬口腔分散膜剂 | |
| JP5429710B2 (ja) | 治療薬剤の標的部位への集積及び放出を追跡可能な治療薬剤含有リポソームおよびその製造方法 | |
| HRP20211564T1 (hr) | Farmaceutska priprema ugljikohidrata za terapijsku uporabu | |
| ES2849750B2 (es) | Capsula galenica rompible | |
| RU2015117412A (ru) | Улучшенный способ получения инкапсулированного в липосомы винкристина для терапевтического применения | |
| CN103655370B (zh) | 一种中药护手霜 |